Regeneron has given up on a CAR-T candidate acquired from 2seventy bio last year before it entered the second part of a phase 1/2 lymphoma study. | Regeneron has given up on a CAR-T candidate acquired ...
Even for a newly minted Nobel laureate, downtime is hard to find. | Even for a newly minted Nobel laureate, downtime is hard ...
The San Diego-based biotech has been evaluating the oral NLRP3 inhibitor, dubbed VTX3232, in a phase 2 study of 175 patients ...
Roche’s diagnostics business continues to be buffeted by China headwinds, but the Swiss major believes it has enough ...
Roche has dropped five Chugai candidates from its clinical pipeline, echoing actions that the Japanese business took earlier ...
Moderna is halting development of an mRNA vaccine for congenital cytomegalovirus after its candidate failed to protect women ...
Parikh is backed up by experienced CRO leader William Gannon Jr., M.D., who is LyfeSci’s chief medical officer. Gannon has ...
In a mixed interim data drop, Arcturus Therapeutics has revealed a lack of efficacy for its investigational inhaled mRNA therapy in cystic fibrosis (CF). | In a mixed interim data drop, Arcturus ...
Alector Therapeutics is shelving a GSK-partnered antibody after the asset failed to slow disease progression in patients with ...
Sanofi’s $1.7 billion rare disease bet from last year has delivered a phase 2 win. | Sanofi’s $1.7 billion rare disease bet ...
Ipsen is acquiring next-gen immuno-oncology biotech ImCheck Therapeutics for its investigational cancer combination therapy ...
Boston Scientific’s third-quarter revenue topped $5 billion, up 20.3% year over year. Growth eased slightly from the second ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback